[ad_1]
A decision on this is scheduled for Monday.
According to the draft prepared, the Government of Lithuania would not approve the purchase of additional doses of the vaccine against the COVID-19 disease envisaged in the preliminary agreement with the pharmaceutical company Janssen Pharmaceutica NV.
“The vaccine is not suitable for maintaining immunity because of its platform,” says SAM.
SAM Chancellor Jurgita Grebenkovienė told BNS that the Janssen vaccine is suitable and effective for developing immunity, but according to currently available data, it is not suitable for revaccination.
Furthermore, according to her, Lithuania has already approved 0.7 million. doses of this vaccine will be delivered at the end of these and will guarantee the need for vaccination.
The government has already approved the purchase of the following vaccines:
- AstraZeneca – 1.86 million doses;
- Janssen Pharmaceutica NV – 0.7 million doses;
- Sanofi Pasteur and GSK – 1.5 million doses;
- CureVac – 1.38 million doses;
- Modern – $ 0.506 million dose;
- BioNTech and Pfizer: 9.296 million doses;
- Novavax – 0.633 million doses;
- Valneva – 0.372 million doses.
Some vaccines are not yet registered with the European Medicines Agency.
